Details

---

Manufacturer
Kagamiishi Plant, Nipro Pharma Corporation(JAPAN)

Registraction Number
MAL19086008ACRZ

Content:

• Active Ingredient: Gefitinib (250 mg per tablet)
• Excipients: Lactose monohydrate (163.5 mg), sodium (3.86 mg), and other inactive ingredients

Indications:
Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR).
Instructions:

• Dosage: One 250 mg tablet once daily. It can be taken with or without food.
• Administration: Take the tablet at the same time each day. If a dose is missed, take it as soon as you remember, but if it's less than 12 hours until the next dose, skip the missed dose.
• Precautions: Do not take antacids 2 hours before or 1 hour after taking Iressa. Patients with moderate to severe hepatic impairment should be closely monitored